Pharmarise Holdings Corporation provided consolidated earnings guidance for the six months and full year of fiscal year ending May 31, 2023. For the six months, the company expects net sales of JPY 25,860 million, operating profit of JPY 768 million, profit attributable to owners of parent of JPY 219 million and earnings per share of JPY 23.40.
For the full year, the company expects net sales of JPY 51,909 million, operating profit of JPY 1,606 million, profit attributable to owners of parent of JPY 543 million and earnings per share of JPY 58.07.